Revolutionizing the treatment of immunological diseases
We are developing first-in-class regulatory B10 cell-based immunotherapies for treating cancers, autoimmunity and immunodeficiency. Our unique technologies can either enhance or inhibit immune responses as needed for disease treatment.
OUR MISSION Our mission is to develop novel immunotherapies that provide patients with improved treatments for cancer, infectious disease, autoimmunity and immunodeficiency.
Three pillars of our work
Technology
We are advancing two B10 cell-based technologies that can either enhance or inhibit immune responses. We believe these have the potential to profoundly advance treatments for inflammation, autoimmunity, solid tumors and infection.
Read more →
Pipeline
Our first-in-class regulatory B10 cell-directed therapies take a unique approach and distinguish us from others working in the immunotherapy area. We have one of the leading pipelines in B cell therapy.
Read more →
Publications
The science behind our technology is well-vetted and supported by numerous peer-reviewed publications.
Read more →Follow Cellective
Be the first to know about our science, pipeline and milestones.